Ionis Announces Olezarsen New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed
Ionis Pharmaceuticals' olezarsen NDA accepted for Priority Review by FDA for FCS treatment, with action date set for December 19, 2024. Phase 3 sHTG program enrollment completed. Olezarsen targets apoC-III to lower triglyceride levels, reducing acute pancreatitis risk in FCS and sHTG patients.
Highlighted Terms
Related News
Ionis Announces Olezarsen New Drug Application Accepted for Priority Review and Enrollment in Phase 3 sHTG Program Completed
Ionis Pharmaceuticals' olezarsen NDA accepted for Priority Review by FDA for FCS treatment, with action date set for December 19, 2024. Phase 3 sHTG program enrollment completed. Olezarsen targets apoC-III to lower triglyceride levels, reducing acute pancreatitis risk in FCS and sHTG patients.